Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

REVB vs KAVL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REVB Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

REVB Overall Winner 6-Pillar Tally: REVB 2 – 2 KAVL (2 Tie) Matrix Metrics: REVB 6 – 2 KAVL

As of Nov 20, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Kaival Brands Innovations Group, Inc (KAVL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). REVB carries a Unified Composite Score of 44.6/100 (HOLD) at $3.50 (0.9x Forward P/E, 0.0% operating margin), whereas KAVL carries 49.1/100 (HOLD) at $0.14 (N/M Forward P/E, -392.1% operating margin).

  • Composite vs. Pillar Nuance: While KAVL currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. REVB 44.6/100 HOLD), REVB captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -392.1% operating margin) and revenue trajectory (+0.0% vs. -80.0% YoY).
  • Technical & Structure Timing Caution: REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1); meanwhile KAVL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REVB vs KAVL
REVB NASDAQ Head-to-Head Winner
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.50
-5.15% 1D
Market Cap $2.1M
TTM Revenue N/A
Forward P/E 0.9x
Beta / 30D Vol 2.88β · 101% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 20.0 Fund 37.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (102.0% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $3.93 · SMA50: $2.29
KAVL NASDAQ
Kaival Brands Innovations Group, Inc
Retail-Nonstore Retailers
$0.14
-12.96% 1D
Market Cap $1.8M
TTM Revenue $1.1M
Forward P/E N/M
Beta / 30D Vol 0.88β · 244% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.5%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $0.34 · SMA50: $0.47

6-Pillar Scorecard Institutional Category Breakdown (REVB 2 – 2 KAVL)

Columns: Metric · REVB · KAVL
1. Valuation Multiples REVB
Forward P/E 0.9x N/M
Trailing P/E 0.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.6x
2. Growth & Scale REVB
Revenue Growth (YoY) +0.0% -80.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.1M
Market Cap $2.1M $1.8M
3. Profitability & Quality KAVL
Gross Margin N/A 82.6%
Operating Margin 0.0% -392.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -133.4% -68.6%
4. Balance Sheet & Cash Flow KAVL
Cash Generation (TTM) N/A -$2.5M
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.58 Book/Sh · -133.4% ROE $0.87 Book/Sh · -68.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Tobacco Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REVB (6) vs KAVL (2)
Institutional Metric REVB KAVL Criterion Row Edge
Market Capitalization
Scale
$2.1M $1.8M Larger Scale Tie
Trailing P/E Ratio
Valuation
0.9x N/M Lower Multiple REVB
Forward P/E Ratio
Valuation
0.9x N/M Lower Multiple REVB
Revenue Growth (YoY)
Growth
+0.0% -80.0% Higher Growth REVB
Operating Margin (TTM)
Profitability
0.0% -392.1% Higher Margin REVB
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-133.4% -68.6% Higher ROE KAVL
52-Week Range Position
Momentum
71% ($0–$5) 1% ($0–$2) Stronger Trend REVB
Beta / 30D Volatility
Risk Regime
2.88β · 101% Vol 0.88β · 244% Vol Lower Realized Risk REVB
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite KAVL
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 82.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.58 Book/Sh · -133.4% ROE) -$2.5M ($0.87 Book/Sh · -68.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REVB +71.46 pp
REVB: +0.41% · KAVL: -71.05%
3M Horizon REVB +71.84 pp
REVB: -0.04% · KAVL: -71.88%
6M Horizon REVB +71.84 pp
REVB: -0.04% · KAVL: -71.88%
1Y Horizon REVB +71.84 pp
REVB: -0.04% · KAVL: -71.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REVB vs KAVL. Trailing 12-month operating profitability (REVB 0.0% vs KAVL -392.1%) and valuation multiples (REVB 0.9x vs KAVL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

REVB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-133.4% · 0.9x
KAVL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.1M
Gross Margin82.6%
Op. Margin-392.1%
ROE / Fwd P/E-68.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REVB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact REVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KAVL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KAVL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KAVL Moat Profile Cyclical / Execution-Driven Positioning
Tobacco Operator
Competes within the Tobacco value chain with $1.8M market capitalization and -392.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REVB vs KAVL Key Questions & Quantitative Answers

As of Nov 20, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Kaival Brands Innovations Group, Inc (KAVL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). REVB carries a Unified Composite Score of 44.6/100 (HOLD) at $3.50 (0.9x Forward P/E, 0.0% operating margin), whereas KAVL carries 49.1/100 (HOLD) at $0.14 (N/M Forward P/E, -392.1% operating margin). Composite vs. Pillar Nuance: While KAVL currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. REVB 44.6/100 HOLD), REVB captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -392.1% operating margin) and revenue trajectory (+0.0% vs. -80.0% YoY). Technical & Structure Timing Caution: REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.1); meanwhile KAVL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REVB leads the Growth & Scale pillar: REVB posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KAVL at -80.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (82.6% gross margin, -392.1% operating margin). On trailing 12-month operating scale, REVB generates N/A in USD-normalized revenue versus $1.1M for KAVL. In operating R&D and SG&A reinvestment, REVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KAVL.

REVB screens cheaper on headline valuation multiples. REVB trades at 0.9x Forward P/E, 0.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KAVL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REVB (-133.4% ROE) versus KAVL (-68.6% ROE) capital efficiency.

In options market volatility and institutional positioning, REVB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.88β · 101% Vol realized risk). By comparison, KAVL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.88β · 244% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.